Warner Chilcott offers potential acquirers the chance to buy a company in a M&A deal, that throws off more cash from selling contraceptives and colitis treatments than any specialty drugmaker in the world.
Shares of the Dublin-based company surged to a nine-month high this week after Warner Chilcott said it’s exploring M&A options and holding talks with possible buyers.
The $5.5 billion company, which gained 27 percent since takeover speculation emerged less than a week ago, still has a free cash flow yield that’s 20 percent of its share price, about 10 times more than the median for comparable drugmakers with at least $1 billion in market value, according to data compiled by Bloomberg.
While analysts are predicting Warner Chilcott’s sales will decline this year as it faces competition from generic copies of its drugs, Invesco Ltd. and RBC Capital Markets said the company could fetch at least $27 a share in a takeover, a 23 percent premium to yesterday’s price.
A larger drug company could benefit by expanding sales of Warner Chilcott’s top brands such as Asacol, which treats intestinal inflammation, and cutting costs to boost profits, Invesco said.
Read: more on M&A deals in pharma, biotech, life science partnering deal news, insights and glossary
Read: Big pharma deal news - latest deal news for top 50 pharma / big pharma companies
Report: Partnering Deals and Alliances with Warner Chilcott
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity